1. M2‐like tumor‐associated macrophages promote epithelial–mesenchymal transition through the transforming growth factor β/Smad/zinc finger e‐box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamous cell carcinoma
   Ryota Sumitomo et al, 2023, Cancer Science CrossRef
2. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer
   Giedrė Gurevičienė et al, 2024, Medicina CrossRef
3. Development of an Albumin-Masked mutPD-1Ig as a Tumor Lesion-Selective Immune Checkpoint Inhibitor
   Chien-Yu Chou et al, 2023, ACS Omega CrossRef
4. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
   Shayista Akbar et al, 2023, Frontiers in Immunology CrossRef
5. IFI16 Induced by Direct Interaction between Esophageal Squamous Cell Carcinomas and Macrophages Promotes Tumor Progression via Secretion of IL-1α
   Yuki Azumi et al, 2023, Cells CrossRef
6. The presence of intratumoral Porphyromonas gingivalis correlates with a previously defined pancreatic adenocarcinoma, immune cell expression phenotype and with tumor resident, adaptive immune receptor features
   Jacob C Kinskey et al, 2023, Carcinogenesis CrossRef
7. Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer
   Yuan Yao et al, 2023, Biomedicine & Pharmacotherapy CrossRef
8. Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
   Xizi Hu et al, 2024, Journal for ImmunoTherapy of Cancer CrossRef
9. Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
   Joe Q. Wei et al, 2023, Biomedicines CrossRef